Astaxanthin (AXT), a carotenoid primarily derived from marine organisms such as shrimp, krill and the microalga Haematococcus pluvialis, has gained significant attention for its potent antioxidant, anti‐inflammatory and anti‐proliferative properties. The present comprehensive review explored the role of AXT in cancer prevention and treatment, emphasizing its cytotoxic mechanisms and modulation of key molecular pathways involved in cancer progression. AXT has demon‐ strated efficacy across a variety of cancer types, including nervous system, breast and gastrointestinal cancers, through its ability to induce apoptosis, inhibit metastasis and disrupt cell growth. The present review detailed both in vitro and in vivo studies highlighting the effectiveness of AXT in sensitizing cancer cells to chemotherapy, thereby enhancing therapeutic outcomes and potentially reducing treatment‐related side effects. The incorporation of AXT in nanoparticle‐based delivery systems has further improved its bioavailability and targeted action, showcasing its potential in advanced cancer therapies. However, despite promising experimental results, more comprehensive in vivo studies and clinical trials are necessary to validate the efficacy and safety of AXT in human populations. Such research would help standardize dosing, confirm interactions with conventional treatments and support the integration of AXT into clinical oncology as a natural, complementary approach to existing cancer treatments

Astaxanthin in cancer therapy and prevention

CHIARA COPAT
Primo
;
CLAUDIA FAVARA
Secondo
;
CARMEN SICA;ALFINA GRASSO;GEA OLIVERI CONTI
Penultimo
;
MARGHERITA FERRANTE
Ultimo
2025-01-01

Abstract

Astaxanthin (AXT), a carotenoid primarily derived from marine organisms such as shrimp, krill and the microalga Haematococcus pluvialis, has gained significant attention for its potent antioxidant, anti‐inflammatory and anti‐proliferative properties. The present comprehensive review explored the role of AXT in cancer prevention and treatment, emphasizing its cytotoxic mechanisms and modulation of key molecular pathways involved in cancer progression. AXT has demon‐ strated efficacy across a variety of cancer types, including nervous system, breast and gastrointestinal cancers, through its ability to induce apoptosis, inhibit metastasis and disrupt cell growth. The present review detailed both in vitro and in vivo studies highlighting the effectiveness of AXT in sensitizing cancer cells to chemotherapy, thereby enhancing therapeutic outcomes and potentially reducing treatment‐related side effects. The incorporation of AXT in nanoparticle‐based delivery systems has further improved its bioavailability and targeted action, showcasing its potential in advanced cancer therapies. However, despite promising experimental results, more comprehensive in vivo studies and clinical trials are necessary to validate the efficacy and safety of AXT in human populations. Such research would help standardize dosing, confirm interactions with conventional treatments and support the integration of AXT into clinical oncology as a natural, complementary approach to existing cancer treatments
2025
astaxanthin, cancer, prevention, therapy, microalga
File in questo prodotto:
File Dimensione Formato  
br_22_4_1944_PDF.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 1.94 MB
Formato Adobe PDF
1.94 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/662650
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact